Table 1.
Baseline characteristics of patients with castration-resistant prostate cancer (CRPC).
| Patient Characteristics | n (%) | 41 (100) |
|---|---|---|
| Mean (standard deviation (SD)) age, years | 75.3 (10.3) | |
| PSA ng/Ml (SD) | 187.9 (378.0) | |
| initial PSA | 1437.7 (2898.2) | |
| Gleason score | n (%) | |
| 3 + 3 = 6 | 3 (7.3) | |
| 3 + 4 = 7 | 2 (4.9) | |
| 4 + 3 = 7 | 3 (7.3) | |
| 4 + 4 = 8 | 9 (21.9) | |
| 4 + 5 = 9 | 16 (39.0) | |
| 5 + 4 = 9 | 4 (9.8) | |
| 5 + 5 = 10 | 4(9.8) | |
| PS | n (%) | |
| 0 | 8 (19.5) | |
| 1 | 22 (53.7) | |
| 2 | 11 (26.8) | |
| Mean LDH U/L (SD) | 260.0 (175.6) | |
| Mean ALP U/L (SD) | 566.3 (771.5) | |
| Mean Hb g/dl (SD) | 11.4 (1.6) | |
| Mean Alb g/dl (SD) | 3.7 (0.6) | |
| All metastasis | n (%) | |
| None | 3 (7.3) | |
| Yes | 38 (92.7) | |
| Lymph node metastasis | n (%) | |
| None | 26 (63.4) | |
| Yes | 15 (36.6) | |
| Visceral metastasis | n (%) | |
| None | 35 (85.4) | |
| Yes | 6 (14.6) | |
| Bone metastasis | n (%) | |
| 0 | 5 (12.2) | |
| 1 to 5 | 14 (34.2) | |
| 6 to 19 | 11 (26.8) | |
| 20 or more | 11 (26.8) | |
| Usage history of Abi and/or Enz | n (%) | |
| None | 11 (26.8) | |
| Yes | 30 (73.2) | |
| Usage history of DTX and/or CBZ | n (%) | |
| None | 26 (63.4) | |
| Yes | 15 (36.6) | |
| Current treatment | n (%) | |
| Abi, Enz | 20 (48.8) | |
| DTX, CBZ | 12 (29.3) | |
| Vintage hormone | 8 (19.5) | |
| Radium223 | 1 (2.4) | |
| Effectiveness of Abi or Enz in the past and present | n * 1 (%) | |
| Progression disease | 21 (70.0) | |
| Stable or response disease | 9 (30.0) | |
| Effectiveness of current treatment | n (%) | |
| Progression disease | 16 (41.0) | |
| Stable or response disease | 23 (59.0) | |
| Treatment line | n (%) | |
| 2 | 19 (46.4) | |
| 3 | 16 (39.0) | |
| 4 | 3 (7.3) | |
| 5 | 2 (4.9) | |
| 6 | 1 (2.4) | |
| Time to CRPC Month (SD) | 28.1 (29.7) | |
| Time from CRPC Month (SD) | 27.4 (18.4) | |
| PAXgene AR-V7 | n (%) | |
| Negative | 19 (46.3) | |
| Positive | 22 (53.7) | |
| Celsee AR-V7 | n (%) | |
| Negative | 32 (78.0) | |
| □ | Positive | 9 (22.0) |
PSA: Prostate-specific antigen, PS: performance status, LDH: lactate dehydrogenase, ALP: alkaline phosphatase, Hb: hemoglobin, Alb: albumin, Abi: abiraterone, Enz: enzalutamide, DTX: docetaxel, CBZ: cabazitaxel, CRPC: castration-resistant prostate cancer. * 1: 30 patients (from 41) received Abi or Enz treatments.